Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain

Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson's disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuropsychopharmacology
Autors principals: Fowler, Joanna S, Logan, Jean, Volkow, Nora D, Shumay, Elena, McCall-Perez, Fred, Jayne, Millard, Wang, Gene-Jack, Alexoff, David L, Apelskog-Torres, Karen, Hubbard, Barbara, Carter, Pauline, King, Payton, Fahn, Stanley, Gilmor, Michelle, Telang, Frank, Shea, Colleen, Xu, Youwen, Muench, Lisa
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4289953/
https://ncbi.nlm.nih.gov/pubmed/25249059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2014.214
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars